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Autoimmune Addison’s disease (AAD) is characterized by the autoimmune destruction of
the adrenal cortex. Low prevalence and complex inheritance have long hindered successful
genetic studies. We here report the first genome-wide association study on AAD, which
identifies nine independent risk loci (P < 5 × 10−8). In addition to loci implicated in lympho-
cyte function and development shared with other autoimmune diseases such as HLA,
BACH2, PTPN22 and CTLA4, we associate two protein-coding alterations in Autoimmune
Regulator (AIRE) with AAD. The strongest, p.R471C (rs74203920, OR= 3.4 (2.7–4.3), P=
9.0 × 10−25) introduces an additional cysteine residue in the zinc-finger motif of the second
PHD domain of the AIRE protein. This unbiased elucidation of the genetic contribution to
development of AAD points to the importance of central immunological tolerance, and
explains 35–41% of heritability (h2).
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Autoimmune Addison’s disease (AAD) is the most com-mon cause of primary adrenal failure in the Westernworld1. It is a rare disease, affecting from five individuals
per million in Japan, to more than 200 per million in the Nordic
countries2,3. The disease requires lifelong steroid hormone
replacement therapy and is fatal if untreated. Autoimmune
etiology is often apparent from the presence of other associated
autoimmune diseases4, and is confirmed by the presence of
autoantibodies against the adrenal enzyme 21-hydroxylase5.
Despite the high heritability of AAD, amounting to 97% in a
Swedish twin study (95% CI 0.88–0.99)6, genetic factors contributing
to disease development have remained poorly defined. Due to the
limited size of previously studied cohorts, candidate gene studies
have for long been the only feasible option, even though the
approach is known to be biased and many results fail to replicate.
Targeted investigations have associated AAD with variation in the
human leukocyte antigen (HLA) region on chromosome 6p217–9,
and have also implicated other well-established autoimmune
disease susceptibility genes such as PTPN2210, CTLA411–13, and
CLEC16A14. Targeted sequencing studies have further identified
BACH215 and AIRE16 as risk loci in AAD, but were limited to
preselected gene panels and small sample sizes. A genome-wide
association study (GWAS) in AAD has hitherto not been possible
due to the insufficient size of available cohorts.
Here we utilize the two largest Addison’s disease biobanks in
the world17,18, enabling us to uncover both known and novel
associations. Most intriguingly, we link AAD to protein-coding
risk variants in AIRE, a gene crucial for antigen presentation in
the thymus and for central immunological tolerance.
Results
GWAS of autoimmune Addison’s disease. Our initial sample of
1457 unrelated cases was further filtered to ensure a homogenous
cohort of patients with autoimmune adrenal failure. We selected
only cases with serum autoantibodies against 21-hydroxylase, and
removed cases with clinical manifestations indicating other dis-
ease etiologies. Individuals with autoimmune polyendocrine
syndrome type-1 (APS-1)4 were identified and excluded using
clinical criteria, cytokine autoantibodies, and AIRE gene
sequencing. The main analysis encompassed 1223 cases with
AAD and 4097 healthy controls (Supplementary Table 1 and
Supplementary Note 1). Genotyping was performed on a single
occasion on the Illumina Infinium Global Screening Array
followed by phasing and imputation. We imputed genotypes from
the Haplotype Reference Consortium, retaining more than 7
million variants with minor allele frequency (MAF) ≥ 1%. The
case–control association was performed using logistic regression
on allele dosages, with sex and the first five principal components
as covariates (Supplementary Fig. 1). The genomic inflation factor
(λGC) was 1.05 and the linkage disequilibrium (LD) score
regression coefficient 1.02 (SE 0.007) indicating a low inflation in
test statistics, mostly due to polygenicity (Supplementary Fig. 2).
We assessed the proportion of heritability explained by
additive effects of SNPs using the genome-wide complex trait
analysis GCTA (genome-wide complex trait analysis) software19.
To account for ascertainment bias, i.e., the enrichment of cases in
our sample compared to the general population, we included
disease prevalence in the calculation. Reports from Scandinavia
have indicated a prevalence between 13 and 22 cases per 100,000
inhabitants, which corresponded to an SNP heritability rate for
AAD between 34 and 40%3,17,20. In other words, 35–41% of the
heritability estimated in twins (h2 ≈ 0.97) is explained by the
SNPs covered in this GWAS6.
Genome-wide significant risk loci. Our genome-wide analysis
identified nine risk loci that exceeded the genome-wide sig-
nificance (P ≤ 5 × 10−8; Fig. 1 and Table 1). Besides the HLA
region, which stood out as the major risk locus (top SNP
rs3998178, P < 10−179), we discovered AAD associations with
variants in or adjacent to PTPN22, CTLA4, LPP, BACH2, SH2B3,
SIGLEC5, UBASH3A, and AIRE (Supplementary Fig. 3). Of these
associated loci, five had previously been implicated in AAD
(PTPN22, CTLA4, HLA, AIRE, and BACH2), underlining the
reliability of our results, whereas four loci were novel: LPP, SH2B3,
SIGLEC5, and UBASH3A. To identify any further independent
signals within the association peaks, we performed conditional
regression analysis on the most significant SNP in each peak.
We also carried out a fine-mapping analysis of each association
peak, bar that centered on HLA, for which the results are
summarized in Supplementary Data 1. Most loci had only one
credible configuration, and those that had several had highly
overlapping ones (2:3 SNPs common to all configurations). When
limited to a single causal SNP, most loci had many SNPs in the
credible set (range 7–43). Only SNPs with a log10(Bayes Factor) > 2,
indicating strong support for causality versus the null hypothesis,
are reported in Supplementary Data 1.
Fig. 1 Manhattan plot for the genome-wide association study of autoimmune Addison’s disease with 1223 cases and 4097 controls. The –log10 P values
from logistic regression on the y-axis are plotted against their physical chromosomal position on the x-axis for all SNPs across chromosomes 1–22 and X.
Labels correspond to the prioritized or nearest genes. The dotted red bar marks the genome-wide significance level (P≤ 5 × 10−8). The y-axis has been
gapped to include the top SNP in the HLA region.
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Association with the Autoimmune Regulator gene. Given that
mutations in AIRE cause the monogenic disease APS-1 (OMIM
#240300), of which AAD is a major component, this association
peak was investigated in particular detail. Conditioning on the
top AIRE SNP rs74203920, we found a second independent signal
in AIRE (rs2075876, Pcond. < 7.8 × 10−14), which was not in LD
with the covariate rs74203920 (r2 < 0.01) (Fig. 2). Of these two
independent associations, the top SNP rs74203920 was a novel
association, whereas rs2075876 has been investigated
previously16.
As we had carefully excluded cases of APS-1 using clinical data,
serology, and genetic information, the strong association with the
lead SNP in AIRE was a striking finding (rs74203920, OR= 3.4
(2.7–4.3), P= 9.0 × 10−25). Comparing carriers with non-carriers
of the p.R471C variant in our group of cases (n= 1223), we could
not detect any differences in age of disease onset or presence of
autoantibodies (Supplementary Table 2). Furthermore, to test
whether the effect of rs74203920-T was associated with AAD
alone or with autoimmune comorbidities, we divided cases into
isolated AAD (n= 443), and those with AAD and type 1 diabetes
or autoimmune thyroid disease, i.e., Autoimmune Polyendocrine
Syndrome type-2 (n= 682) (Table 2)4. The risk allele
rs74203920-T was equally enriched in both categories, and
exceeded genome-wide significance regardless of autoimmune
comorbidity.
Since APS-1 is a recessive disorder, we formally tested but
could not find support for rs74203920 and/or rs2075876 causing
AAD with recessive inheritance (Supplementary Table 3). Rather,
the risk effects of both SNPs were best described by an additive
model. Lastly, we tested for differential association with other loci
in carriers versus non-carriers of rs74203920 and rs2075876,
respectively, but found no differences between the groups
(Supplementary Tables 4 and 5). Taken together, the associated
AIRE variants exert their risk effect independently from each
other and from other risk loci.
The risk allele rs74203920-T was uncommon in our Swedish
and Norwegian controls (2.0%) and in the non-Finnish European
population (1.4% GnomAD v2.1.1), but was strongly enriched
among cases with AAD (MAF= 6.5%). The SNP is located in
exon 12 and the risk allele encodes an arginine to cysteine
substitution at amino acid residue 471 in the well-conserved zinc
ion binding motif of the second PHD domain (PHD2) (Fig. 2a).
The PHD2 domain of AIRE is stabilized by a zinc finger with two
zinc ions, one of which is coordinated by amino acid residues
C446, C449, C472, and C47521. Each zinc-binding residue is
essential, as exemplified by the missense mutation p.C446G found
in patients with APS-1, which destroys the structural fold of the
PHD2 domain. By introducing an additional cysteine in the zinc-
binding motif, it is possible that p.R471C alters the binding of the
zinc ion and the structure of the PHD2 domain (Fig. 2b and
Supplementary Fig. 4).
Within the second, independent association peak in AIRE, the
top SNP rs2075876 was in LD with the coding SNP rs1800520
(r2= 0.83). This variant, a serine to arginine substitution of amino
acid residue 278 (p.S278R), is located in the SAND domain.
Hence, two coding changes were independently associated with
AAD. In a functional assay of AIRE function, neither .R471C nor
p.S278R interfered with AIRE-dependent transcription (Supple-
mentary Fig. 5 and Supplementary Note 2)22. With two
independent associations with AIRE, AIRE-dependent antigen
presentation, and central immune tolerance appears to play an
important role in the development of AAD.
Dissection of the HLA association. The HLA region is by far the
strongest risk locus in AAD, but due to long-range LD and genetic
heterogeneity, the dissection of risk within the region is challen-
ging. To define the key components of genetic risk attributable to
HLA, we imputed classical HLA alleles and their corresponding
amino acids across HLA class I and class II, and constructed a
general logistic model for AAD risk (Fig. 3 and Supplementary
Note 3). We report seven independent alleles and amino acids
associated with AAD at the genome-wide significance level
(P value <5 × 10−8; Table 3). Consistent with previous studies, we
found that the risk was dominated by HLA-DQB1*02:01 (OR=
7.3, P= 1.9 × 10−45, under the full model including all reported
effects), and HLA-DQB1*03:02 (OR= 2.3, P= 1.4 × 10−21), that
tag the well-established risk haplotypes corresponding to serotypes
DR3-DQ2 and DR4-DQ8, respectively9,16,17. We also found lar-
gely additive risks for DQB1 position 30 Tyr, B pos. 74 Asp, B pos.
156 Asp, and DQA1*01:04. The tyrosine residue in position 74 of
HLA-B was the first representation of HLA class I to be included
in the model, and had only a weak correlation with HLA class II
(r2= 0.22 with HLA-DQB1*02:01). Comparing cases (n= 232)
Table 1 Autoimmune Addison’s disease risk loci.
Risk allele frequency Association
Locusa Chr: Positionb SNP Typec Risk/alt alleled Cases Controls OR (95% CI) P
PTPN22 1: 114377568 rs2476601 p.R620W A/G 0.17 0.11 1.74 (1.53–1.98) 6.3 × 10−17
CTLA4 2: 204707138 rs11571303 25 kb G/A 0.69 0.61 1.39 (1.26–1.53) 5.0 × 10−11
LPP 3: 188112554 rs1464510 intronic A/C 0.51 0.42 1.37 (1.25–1.5) 7.3 × 10−12
HLA-DQB1 6: 32623371 rs3998178 4 kb T/C 0.51 0.19 5.98 (5.29–6.76) 3.5 × 10−179
BACH2 6: 90926612 rs10806425 5′ UTR A/C 0.50 0.37 1.69 (1.53–1.85) 2.8 × 10−27
SH2B3 12: 111932800 rs7137828 43 kb C/T 0.53 0.46 1.3 (1.18–1.42) 4.9 × 10−8
SIGLEC5 19: 52204248 rs8112143 70 kb A/G 0.073 0.047 1.88 (1.51–2.34) 1.4 × 10−8
UBASH3A 21: 43836186 rs11203203 intronic A/G 0.42 0.35 1.35 (1.22–1.48) 8.6 × 10−10
AIRE 21: 45714294 rs74203920 p.R471C T/C 0.065 0.020 3.42 (2.71–4.32) 9.0 × 10−25
AIREe 21: 45709153 rs2075876 intronic G/A 0.95 0.90 2.17 (1.77–2.66) 7.8 × 10−14
Odds ratios and P values were estimated using logistic regression in 1223 cases diagnosed with autoimmune Addison’s disease and 4097 controls. Only results with P < 5 × 10−8 were reported to adjust
for multiple testing.
a The association peaks in chromosomes 1, 2, 12, and 19, span more than one gene, and the prioritized genes are reported. For HLA, the gene closest to the top SNP is reported.
b Base-pair coordinates according to human reference genome GRCh37.
c Functional characterization of SNPs overlapping prioritized genes, or distance from the SNP to the prioritized gene.
d The risk allele indicates the effect allele for the OR, the second position gives the alternative allele.
e Results for AIRE rs2075876 are from an analysis conditioning on the genotypes of the top SNP in AIRE, rs74203920.
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Fig. 2 Two coding variants in the Autoimmune Regulator gene (AIRE) are independently associated with autoimmune Addison’s disease. a GWAS
results without (upper panel) and with (lower panel) conditioning, on the top SNP rs74203920. The secondary association peak, including rs1800520,
remains equally significant after conditioning reflecting its independent association. The –log10 P values from logistic regression of 1223 cases and 4097
controls are plotted against their physical chromosomal position. The red bars represent the genome-wide significance level (5 × 10−8). b The location and
consequences of the coding change p.R471C in the PHD2 domain of AIRE. The additional charge from the cysteine residue (red) is in close proximity to the
zinc ion (teal). Arginine is marked in green, histidine in orange, and wildtype (WT) cysteines in yellow.
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and controls (n= 2719) that carry neither of the major two risk
haplotypes, the two strongest of remaining risk haplotypes con-
tained DQB1*03:01 and DQB1*04:02, both of which encode a
tyrosine residue in DQB1 position 30.
After defining the major risk effects, we next investigated the
presence of interactions between HLA alleles and amino acids
included in the model, and all other alleles and residues in the
dataset. We identified a strong risk effect for DRB1*04:04 in the
presence of DQB1*02:01 (OR= 6.7, P= 1.4 × 10−22). Beside this
interaction, no other pairs of alleles and/or residues passed the
significance threshold for inclusion in the full model.
To avoid the risk of conditioning out critical amino acids in
local LD with major risk alleles, we extracted and investigated the
most significantly associated residues from each round of the
stepwise regression (Supplementary Table 6). The emerging
amino acids were the arginine in position 52 of DQA1 (OR= 7.8,
P= 2 × 10−157) and the alanine in position 57 of DQB1 (OR=
4.3, P= 2.6 × 10−152). The latter is a distinctive feature of the
allele DQB1*02:01. Even though the long-ranging LD in the HLA
region makes it difficult to pinpoint causal variation, it is striking
that also the third independent amino acid resides in the binding
pocket of the HLA-DQ heterodimer (DQB1 pos. 30 tyrosine,
OR= 3.6, P= 3.8 × 10−35) (Fig. 4).
Established loci in AAD. The PTPN22, CTLA4, and BACH2 loci
are well-known drivers of autoimmune disease and we identified
the variants and haplotype blocks that have previously been
described in AAD and common autoimmune comorbidities
(Fig. 5 and Supplementary Figs. 6 and 7). The fine-mapping
analysis largely confirmed the missense variant in PTPN22,
thought to be causal in a range of different autoimmune diseases.
The credible set also included two eQTLs for BCL2L15, a weakly
proapoptotic protein associated with autoimmune thyroid disease
and type 1 diabetes23,24, in T helper cells. This differential reg-
ulation might constitute a secondary causal effect in addition to
the canonical p.R620W variant in PTPN22.
For the chromosome 2 peak, no obviously immune relevant
signals were identified in the credible set/configuration, though a
couple of variants were located in enhancer-like sequences, and a
GTEx eQTL gene for our prioritized CTLA4. In chromosome 6,
almost all the variants in the credible set and configurations were
BACH2 eQTLs for naive T-cell populations in particular, several
also have enhancer-like signatures and exhibit H3K27Ac-marks
in some ENCODE cell lines, strengthening the postulation that
AAD is driven by differential regulation of BACH2 in cases versus
controls.
Novel loci in AAD. We also discovered four novel loci that
achieved genome-wide significance for association with AAD.
The ORs were lower than for loci detected previously, com-
mensurate with the improved statistical power in this study. All
the SNPs in the credible set and configuration for the chromo-
some 3 peak were located in introns of LPP, as is the lead SNP
from the GWAS. With the exception of some weak transcription
factor binding sites, there were no functional categories located at
any of these SNPs.
The association peaks in chromosomes 12 and 19 encompassed
several genes, but were ascribed to SH2B3 and SIGLEC5 after
gene prioritization. The lead SNPs were barely genome-wide
significant, and the most significant genotyped markers, as
opposed to imputed markers, had P values of 7.8 × 10−8 and
4.3 × 10−7 for SH2B3 and SIGLEC5, respectively.
The broad association at the SH2B3 locus looked similar in
studies of type 1 diabetes and vitiligo, giving credibility to the
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Fig. 3 Stepwise regression of the HLA association identifies the major genetic determinants of autoimmune Addison’s disease. The figure displays the
results from the first six steps of regression modeling of the HLA risk effects—alleles and amino acids. Starting with a baseline model comprising sex and
five principal components as covariates, we tested every allele and amino acid in turn for association with AAD (Supplementary Note). Additive, recessive,
dominant, overdominant, and general variable encodings were compared with likelihood ratio tests and/or Bayesian information criterion. The allele or
amino acid residue with most compelling evidence for association was included in the model at every step, and reconsidered at all subsequent steps.
Downstream regression models were conditioned on the effects selected from previous models. The y-axes show the –log10 P values from stepwise logistic
regressions of 1223 cases and 4097 controls. The dashed horizontal lines indicate genome-wide significance (P < 5 × 10−8). Diamonds mark the most
significant effect. Blue color indicates strong linkage disequilibrium (r2) with the most significant effect, gray color indicates no correlation.
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gene. The credible set and configuration for chromosome 12
were eQTLs for a number of tissues and a handful of genes
(mostly the same for each variant) and H3K27Ac-marks in
several cell lines, but none that appeared particularly relevant to
autoimmunity. However, one of the credible set SNPs is both
located in an enhancer-like sequence and is itself a missense
variant in SH2B3. This variant (p.W262R, MAF ≈ 0.5) is not
predicted to be deleterious (by SIFT/PolyPhen). In the
chromosome 19 credible set/configuration, whole blood
eQTLs were present in one variant each for SIGLEC14 (a
MAPK/AKT-activating SIGLEC, as opposed to the DEPICT-
prioritizedSIGLEC5) and SPACA6.
In contrast to the above broad association peaks, the peak at
the UBASH3A locus was well-defined and in a haplotype block
containing no other genes but UBASH3A. eQTLs for UBASH3A
exist for all credible configuration SNPs for various T-cell
subpopulations, but all the variants in this locus’s credible
configurations and sets are yet more significant eQTLs for all
T cells in TMPRSS3.
Interestingly, most AAD GWAS peaks harbor a gene with a
role in or near the immunological synapse, the connection
between antigen-presenting cells and lymphocytes (P= 0.003)
(Supplementary Fig. 8)25.
Genetic correlations and loci shared with other autoimmune
traits. Many autoimmune diseases co-occur in affected indivi-
duals and families, and share numerous genetic risk factors26. To
explore the genetic architecture underlying AAD at large, we
investigated the overlap of risk loci with diseases and traits pre-
viously investigated in other well-powered GWAS. By unsu-
pervised clustering of overlapping risk loci, an extensive and
complex sharing of risk loci among immunological diseases
clearly emerged (Fig. 5a). Systemic autoimmune diseases,
inflammatory bowel diseases, and organ-specific autoimmune
diseases, respectively, formed distinct groups within this major
cluster. The majority of patients with AAD develop at least one
additional autoimmune disease, such as Hashimoto’s thyroiditis,
type 1 diabetes, vitiligo, or Graves’ disease18. It was therefore
interesting to note that AAD displayed a significant overlap of
genetic risk loci with its most common comorbidities, reflecting
the genetic risk factors shared between organ-specific auto-
immune diseases.
We searched the National Human Genome Research
Institute—European Bioinformatics Institute (EBI) GWAS
catalog using our genome-wide significant AAD risk loci for
associations with other autoimmune diseases (Fig. 5b, c). The
overlapping loci included UBASH3A and SH2B3 in type 1
diabetes and celiac disease, and LPP in autoimmune thyroid
disease and vitiligo. In general, surveying autoimmune diseases
with summary statistics available through the GWAS catalog
and PhenoScanner, risk variants and haplotypes were strikingly
often shared across diseases (Supplementary Figs. 6 and 7)27,28.
In the case of PTPN22, which had data available for the largest
number of diseases, confidence intervals of effect estimates
were overlapping between diseases, indicating equivalent effects
(Fig. 5d).
Notably, the strongest of our novel risk alleles, our lead SNP
in AIRE (rs74203920), has not been linked to other auto-
immune diseases in GWAS. Although our second independent
signal in AIRE has previously been associated with AAD, and
also with rheumatoid arthritis in East Asia16,29,30, the allele that
increases the susceptibility to AAD (rs2075876-G), appears
associated with decreased risk of rheumatoid arthritis. Thus,
risk alleles at most loci appear to be general drivers of
autoimmunity, whereas the risk alleles in AIRE are more
specifically associated with AAD.
Discussion
This GWAS of AAD identified nine genome-wide significant
associations and explained 35–41% of the additive genetic herit-
ability (h2). The results point to the complex network of antigen
presentation and immunomodulation that underlie autoimmune
disease development (Fig. 6). In particular, two independent
associations in AIRE highlight the importance of central immune
tolerance in AAD pathogenesis. AIRE is essential for thymic
expression of otherwise tissue-specific proteins, and hence
important for negative selection of autoreactive thymocytes and
prevention of organ-specific autoimmune disease. As strongly
deleterious mutations in AIRE cause APS-1, it is particularly
interesting that we associate two LD-independent protein-coding
variants in AIRE with sporadic AAD.
Given the allele frequency of 1.5–2.0% in the general popula-
tion, the effect of the variant with the strongest association,
p.R471C, must be subtle compared to mutations known to cause
APS-1. p.R471C has previously been reported in single cases of
multi-organ autoimmunity, including patients with AAD and
type 1 diabetes31, or AAD and autoimmune thyroiditis32. None of
the reported cases had interferon autoantibodies, which would be
expected in patients with APS-133. Thus, current evidence does
not support p.R471C as a cause of APS-1, but instead points to an
increased risk of AAD at the population level.
p.R471 is located near two highly conserved cysteine residues
that coordinate a critical zinc ion in the second PHD zinc finger
(p.C472 and p.C475). PHD fingers maintain the structural
integrity, read methylation states of histones, and regulate gene
expression through formation of complexes with chromatin
regulators and transcription factors34. Our transfection assay did
not show an effect of rs74203920 or rs1800520 on AIRE-
dependent transcription, for which there may be several reasons.
While AIRE is predominantly expressed and exerts its main
functions in the thymus, HEK293 cells have despite their renal
origin shown large overlap in AIRE-regulated genes with primary
thymic cells from mice35–37. It is thus likely that p.R471C has an
effect on AAD susceptibility that differs from classical deleterious
mutations that cause APS-1. Furthermore, though it cannot be
excluded that variation in other nearby genes is involved, for
instance the inducible T-cell costimulator (ICOSLG), the credible
set from fine-mapping of the locus includes only p.R471C.
The HLA region is implicated in autoimmune disease and
confers by far the largest risk for AAD compared to other known
risk loci. We dissected the HLA-mediated risk of AAD in detail,
confirming known associations and suggesting additional sus-
ceptibility alleles8,9,15,38. Our results demonstrate that risk is
dominated by alleles in HLA class II, in particular the two major
risk haplotypes, and an interaction between the two indicates a
shared mechanism. We also identified strong effects mediated by
HLA class I. For instance, aspartic acid in residues 74 and 156 of
HLA-B are both represented in HLA-B*08:01, one of the few
alleles that have been successfully investigated in functional stu-
dies on antigen presentation of 21-hydroxylase in AAD
patients39. Notably, we could not detect any interactions between
HLA class I and class II, nor any interactions between pairs of
alleles conferring risk and protection. With a larger sample size,
however, additional effects could potentially be uncovered and
incorporated in a similar model. These results provide a foun-
dation for further work aimed at understanding the exact
mechanisms underlying HLA-mediated risk and for functional
studies of implicated HLA alleles in antigen presentation.
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The two independent associations with AIRE point to altera-
tions in central immunological tolerance as an underlying
mechanism in AAD development. The importance of a correct
expression of AIRE for maintaining immunological tolerance is
also exemplified by Down Syndrome in which the extra copy of
AIRE, located on chromosome 21, has been coupled to altered
expression of AIRE in the thymus, impaired central tolerance and
an overrepresentation of autoimmune diseases40,41. Many of the
other risk loci identified in this study harbor genes involved in
antigen presentation and recognition, and hence in thymocyte
maturation. Beside HLA class II that presents antigens to devel-
oping T cells, the turnover of the T-cell antigen receptor (TCR)
complex is regulated by UBASH3A42, and the immune check-
point CTLA4 modulates the co-stimulation required for T-cell
activation43. Alternatively, or in addition to UBASH3A, the
putative causal variants identified by fine-mapping suggest a role
in AAD for TMPRSS3 in T cells; the risk alleles are linked to
higher expression levels, an effect also seen in type 1 diabetes44.
The tryptophan substitution in position 620 of PTPN22 (p.
R620W) disrupts the formation of complexes between PTPN22
and CSK, and the inhibitory effect on TCR signaling is atte-
nuated45. BACH2 has been shown to stimulate (CD8+) T-cell
differentiation by controlling access of transcription factors to
their enhancers and to promote differentiation of regulatory T
cells46. SH2B3, suggested to be the causal entity behind the
common autoimmune ATXN2/SH2B3 association47, like UBA-
SH3A above, is an inhibitor of signaling cascades in lympho-
cytes47. While the most highly associated variants lie nearer the 5′
end of the gene, LPP harbors a microRNA, miR-28, that appears
to be involved in posttranscriptional regulation of PD148,49 which
has an important role in self-tolerance, restraining autoreactive
T cells and promoting Tregs50.
The association peak on chromosome 19 provides three dif-
ferent potentially causal units: SIGLEC5 (prioritized by DEPICT),




















































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4 Associated amino acids in the HLA-DQ heterodimer. Two amino
acids in HLA-DQB1 and one amino acid in HLA-DQA1 were found to be
associated with autoimmune Addison’s disease. A tyrosine at the 30th
position and an alanine at the 57th position of HLA-DQB1 (top) and an
arginine at the 52nd position of HLA-DQA1 (bottom) have been marked in
orange. To visualize the binding pocket, a peptide ligand (gliadin) from the
original crystal structure has been marked in pink.
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Fig. 5 Shared genetic features. a Human diseases and traits studied in GWAS were clustered to reveal shared genetic risk factors. Diseases/traits are
ordered by unsupervised hierarchical clustering, and color scale indicates genetic correlation. b Loci implicated in autoimmune Addison’s disease in order
of decreasing effect size (odds ratio and 95% CI), 1223 cases, and 4097 controls. The horizontal, dashed line marks OR= 1. Blue squares indicate genome-
wide significant associations for the diseases and loci/variants, respectively. c Circos plot representing the loci associated with AAD (boxes) and other
autoimmune diseases (dots). The AAD track is highlighted in yellow, and the yellow wedge on chromosome 21 is magnified ×15. SLE-systemic lupus
erythematosus, RA-rheumatoid arthritis, PSO-psoriasis, MS-multiple sclerosis, T1D-type 1 diabetes, VIT-vitiligo, CD-coeliac disease. d Side-by-side
comparison of association statistics at the PTPN22 locus across a selection of autoimmune diseases. AAD statistics were calculated using logistic
regression for 1223 cases and 4097 controls.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21015-8 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:959 | https://doi.org/10.1038/s41467-021-21015-8 |www.nature.com/naturecommunications 9
SPACA6 (whole blood eQTL in the credible set). The latter har-
bors miR-125a, a miRNA that appears to be involved in post-
transcriptional regulation of KLF1351, which in turn regulates
CCL5, a chemokine that affects the activation, migration, and
proliferation of T cells52. SIGLEC14, an activating receptor highly
homologous to the nearby SIGLEC5, is hard to rule out, though
the interpretation is further complicated by the fact that a com-
mon polymorphism leads to a SIGLEC14/5 fusion gene and
effectively a SIGLEC14-null phenotype53. SIGLEC5, as it recog-
nizes self-cell surface sialoglycans and mediates inhibitory sig-
naling in T cells54, is the most likely candidate from a cell biology
standpoint. Figure 6 summarizes and highlights these T-cell-
related effects of the most likely functional gene products asso-
ciated with our GWAS hits.
We identified robust association signals despite relatively
modest sample sizes compared to many other autoimmune dis-
orders, which indicate a rather homogenous disease etiology with
relatively low polygenicity compared to other diseases, under-
pinning the high heritability estimates from epidemiological
studies. We believe that a strength of this study was the oppor-
tunity to recruit the majority of AAD patients in Norway and
Sweden through national registries with geographically matched
controls, using stringent exclusion criteria and only including
those with 21-hydroxylase autoantibodies.
To conclude, our results highlight the importance of central
immune tolerance in the development of AAD. Dysregulation of
antigen presentation in the setting of negative selection in the
thymus may be one of the factors that makes AAD exceptional
among organ-specific autoimmune diseases, and the pathways
identified should be explored in the development of preventive
treatment strategies.
Methods
Subjects. Cases were recruited from the Swedish and Norwegian Addison
Registries and fulfilled clinical diagnostic criteria for primary adrenal insuffi-
ciency, i.e., low serum cortisol with a compensatory increase in plasma adre-
nocorticotropic hormone1,17,18. In case of doubt, a corticotropin stimulation test
was performed. Autoimmune etiology was confirmed by the presence of highly
specific autoantibodies targeting the adrenal-specific enzyme 21-hydroxylase, the
major autoantigen in AAD5. Cases were screened for APS-1 using clinical cri-
teria, autoantibodies against interferon-α, interferon-ω, or interleukin 22, and/or
AIRE gene sequencing55,56. Healthy controls were recruited from blood donor
centers across Sweden and Norway to match the geographical coverage of
registry cases.
All study subjects gave their informed consent. The study was performed in
accordance with the Declaration of Helsinki and approved by the local ethics
committees in Stockholm, Sweden (dnr 2008/296-31/2), and Western Norway
(biobank 2013-1504, project 2017-624).
DNA extraction. Blood samples were kept at −80 °C until processed at the HUNT
Laboratory (Levanger, Norway). DNA was isolated using the MasterPure™ DNA
purification kit version II B1 (Epicenter®, Madison WI), and normalized to 50 ng/
µl. In total, 200 ng of each sample was pipetted by robot to 96-well plates (Abgene
Storage Plates, ThermoFisher). Swedish/Norwegian and case/control samples were
distributed in equal proportions in the plates. Technical replicates were included to
facilitate quality control and genotype concordance between plates.
Genotyping, imputation, and quality control. Genome-wide genotyping of
692,367 markers was performed using the Illumina Infinum Global Screening
Array 1.0 by the Human Genomics Facility at Erasmus MC (Rotterdam, the
Netherlands). Markers and samples were filtered iteratively using PLINK version
1.9 (Supplementary Note 1)57. In short, markers were first excluded based on call
rate <95% or deviation from GenomeStudio genotype clusters. Second, samples
were excluded on the basis of sample call rates <98%. Third, in-depth marker
quality control excluded markers with call rate <98%, discordant calls in technical
replicates, or deviation from Hardy–Weinberg equilibrium (HWE, P < 10−6). For X
chromosome markers, HWE tests were performed in females only. Finally, samples
with accumulated heterozygosity >0.34 were excluded.
Bi-allelic SNPs that passed the above QC thresholds and that were present in
the Haplotype Reference Consortium panel58 were used for phasing and
imputation. Genotypes were phased in-house to take advantage of available
pedigree information (SHAPEIT version 2.r837)59, and non-typed variants
imputed using the Sanger Imputation Service (PBWT) and the Haplotype
Reference Consortium release 1.158. Markers with imputation quality score >0.5
and MAF > 0.01 were included in the GWAS.
Global ancestry was inferred using the LASER/TRACE software60 with the
Human Genome Diversity Project reference panel61. Samples estimated to be non-
European were excluded. Genetic relatedness was evaluated using high-quality
markers pruned for LD in PLINK. For each pair of related samples (π̂ > 0.1), cases
and males were preferentially selected, otherwise the sample with the highest call
rate was retained. In total, data from 5320 samples and 7.1 million markers were
kept for association testing.
GWAS. Main axes of genetic variation, as a proxy for population substructure,
were assessed using principal component analysis of high-quality markers with
MAF > 0.05, pruned for LD (r2 < 0.2), and excluding the extended HLA region.
Association statistics were calculated using logistic regression of disease status on
genotype dosages. Sex and the top five principal components were included as
covariates to account for potential sex differences and confounding population
stratification.
Conditional analysis. Loci passing the genome-wide significance threshold for
association were subject to conditional analysis to identify any independent asso-
ciations. This was done by stepwise inclusion of imputed genotype dosages for the
index variants as covariates in logistic regression.
Gene prioritization at associated loci. Enrichment of association signals in
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Fig. 6 T-cell regulation and AAD GWAS associated regions. a Graphic representation of selected aspects of T-cell regulation, with gene products
implicated by GWAS association proximity in red (antigen-presenting cell, APC). b AIRE activity in medullary thymic epithelial cell (mTEC), promoting
expression of tissue-restricted antigens (TRAs) for the education of T cells.
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each association, was performed using the computational tool DEPICT from
GWAS summary statistics (Data-driven Expression Prioritized Integration for
Complex Traits, https://broadinstitute.org/mpg/depict/)25. We used default settings
with 500 permutations to adjust for gene length differences, and 50 repetitions to
compute false discovery rates. The false discovery rate was set to 5%. Associated
loci were plotted with LocusZoom62.
Fine-mapping. Fine-mapping was carried out using FINEMAP63, in two runs. In
total, 1 Mb windows around the lead SNPs for each genome-wide association peak
(except that of HLA) were assessed, allowing maximum one or three causal SNPs
per window per run, and otherwise default settings. It must, however, be noted that
for small studies, such as ours is in a modern GWAS context, the benefits of such
stochastic fine-mapping are likely to be small64.
HLA imputation and dissection. Classical HLA alleles were imputed from
directly genotyped and phased SNPs using HIBAG kernel version 1.465 and
SNP2HLA version 1.0.366. The classifiers and reference panels for European
samples provided with each software were used to impute two field (four digit)
alleles in HLA-A, -B, -C, -DQA1, -DQB1, and -DRB1. To improve the precision of
DRB1-allele calls, we built a model for HLA imputation using a reference panel of
699 healthy Norwegian controls. The DRB1 alleles were called by combining
predictions from the default and in-house model, both weighted by the size of
their training data. Genotypes were kept and treated as fixed if their posterior
probability was at least 0.5 and more than twice as likely as the second most
probable call. For 370 of the case samples, laboratory typing of HLA-A, -B (most
single field), -DQB1, and -DRB1 (most two field) was available. Concordance for
the three former was 92–98% for both HIBAG and SNP2HLA, while it was 90%
for DRB1.
We aimed at identifying the main drivers of risk mediated by classical HLA
alleles and amino acids across HLA class I and class II, with a method adapted
from Moutsianas et al.67. For every HLA allele in turn, we constructed several
logistic regression models and used Bayesian information criterion and likelihood
ratio test to help decide whether the effect was best described as additive,
recessive, dominant, overdominant, or general. See the Supplementary Note 3 for
details of the selection procedure. In short, the allele or amino acid residue effect
from the most significant model was considered for inclusion in the full model.
Five PCs and sex were included as covariates in all models. PCs were calculated
from SNPs genome-wide, not including the HLA region, i.e., the same covariates
as in the GWAS analysis. We only considered the inclusion of alleles/amino acids
that met genome-wide significance P < 5 × 10−8, both at time of inclusion, and in
the final model. Backward elimination was performed by leaving previous
variables out of the current model, one by one, and by subsequently testing the
goodness of fit.
Loci shared with common diseases and traits. Genetic overlap was investigated
using a method adapted from Farh et al.68. In short, GWAS catalog data were
obtained from the EMBL-EBI website (https://ebi.ac.uk/gwas/), current as of
December 201969. Diseases/traits with at least six reported associations (P ≤ 1 × 10−6)
were included. Because many diseases/traits have been subject to more than one
independent GWAS, they had multiple associated SNPs at the same locus. For these
loci, defined as a window of 500 kb, only the most significant index SNP was con-
sidered. In total, 1990 diseases/traits and 5349 SNPs fulfilled the criteria and were used
to find associations where index SNPs of two diseases/traits were within 500 kb of
each other. Overlapping risk loci were used to compute a disease-by-disease corre-
lation matrix for every pair of diseases/traits. We selected 22 autoimmune and 19
representative non-autoimmune diseases/traits for comparison and visualization in
Fig. 5a as well as summary statistics from four autoimmune diseases for in-depth
locus comparison70–73.
We also used LD score regression to calculate genetic correlation between our
GWAS results and 844 predefined traits at the LD Hub (http://ldsc.broadinstitute.
org)74. LD score regression uses GWAS summary statistics of complex traits and
diseases but excludes the HLA region, limiting its capacity for estimating genetic
correlations between traits with a large proportion of their heritability explained by
variation in the HLA.
3D models of the second PHD domain in AIRE. To visualize the associated
amino acids in the HLA-DQA1 and HLA-DQB1 genes, the x-ray diffraction
model of HLA-DQ2.3 (DQA1*03:01/DQB1*02:01) was used (Protein Data
Bank 20 id: 4D8P)75. In order to generate protein models of the PHD2 domain
and the potential structural impact of AIRE variants associated in this GWAS,
we used the previously published NMR structure for PHD2 as a template
(Protein Data Bank 20 id: 2LRI)21. This domain structure was subsequently
mutated at the p.R471 position to a cysteine and visualized using PyMOL
(https://pymol.org/).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Summary statistics that support the findings of this study have been deposited in the
NHGRI-EBI GWAS catalog with the accession code GCST90011871. The individual level
genotype data are not publicly available since they contain information that could
compromise research participant privacy and consent.
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